The Lancet Oncology· Kaixiong Tao, Zhenyu Lin, Peng Zhang, Pan Chi, Yi Xiao, Zhiguo Hou, Ximing Xu, Aimin Zhang, Xingfeng Qiu, Junxin Wu, Ying Yuan, Zhenning Wang, Xiujuan Qu, Xin Li, Xiu Nie, Ming Yang, Kailin Cai, Zheng Wang, Weikang Zhang, Ying Huang, Zhen Sun, Rongrong Zheng, Feng Zhao, Chuyi Han, Tao Zhang·· 4 hours agoPickScore63
[Articles] Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial
In brief
A prespecified interim analysis of the multicentre, open-label, phase 3 UNION trial showed that neoadjuvant short-course radiotherapy plus camrelizumab and CAPOX significantly improved 3-year event-free survival in locally advanced rectal cancer compared with standard long-course chemoradiotherapy plus CAPOX, with a similar safety profile. The investigators consider this new approach worth further comparison with contemporary total neoadjuvant therapy strategies.
Why it matters
Phase 3 interim analysis shows short-course radiotherapy plus camrelizumab and CAPOX significantly improved 3-year event-free survival with safety comparable to standard long-course chemoradiotherapy.
Source: The Lancet Oncology · thelancet.com